US-China Economic Consensus: A preliminary agreement between China and the US on economic and trade issues boosted Hong Kong stocks, with the Hang Seng Index rising 267 points to close at 26,427.
AI and Chip Stocks Surge: Stocks related to AI and semiconductors saw significant gains, with notable increases in companies like Alibaba, Baidu, and SMIC, reflecting strong market interest.
Automotive Market Outlook: The China Passenger Car Association reported reduced inventory pressure for passenger cars, predicting robust sales for manufacturers like BYD and NIO, which also saw their stock prices rise.
Pharmaceutical Sector Performance: Wuxi Apptec reported an 85% profit increase for the first three quarters, leading to a 6% surge in its stock price, while other pharmaceutical stocks also experienced gains.
Wall Street analysts forecast 00522 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00522 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 00522 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00522 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 94.350
Low
Averages
High
Current: 94.350
Low
Averages
High
Citi
Buy
downgrade
$80 -> $98
Al Analysis
2025-10-31
Reason
Citi
Price Target
$80 -> $98
Al Analysis
2025-10-31
downgrade
Buy
Reason
The analyst rating for ASMPT (00522.HK) is maintained at "Buy" despite a miss in 3Q25 results due to several factors, including one-off factory shutdown costs, an unfavorable product mix, and higher operating expenses. The management's optimism for 2026 and 2027, driven by the company's technological leadership in advanced packaging solutions and a recovery in demand from AI and China's NEV sector, supports this rating. Although the broker lowered its earnings forecasts for 2025-2027 to reflect a slower-than-expected recovery in gross profit margins, the outlook for SMT and mainstream semiconductor businesses remains positive, prompting the broker to raise the target price from $80 to $98.
Morgan Stanley
Morgan Stanley
NULL -> Overweight
upgrade
$80 -> $100
2025-10-22
Reason
Morgan Stanley
Morgan Stanley
Price Target
$80 -> $100
2025-10-22
upgrade
NULL -> Overweight
Reason
Morgan Stanley rated ASMPT (00522.HK) as Overweight due to several long-term growth drivers, including the expansion of CoWoS-L output, the development of high-bandwidth memory in China, and progress in hybrid bonding. Despite the expectation of a loss in 3Q25 due to one-off restructuring costs, the broker noted a recovery in mainstream semiconductor demand and continued growth in the advanced packaging market. Additionally, they estimated that ASMPT's book-to-bill ratio would remain above 1 in 3Q25, which supports their positive outlook. Consequently, they raised the target price from $80 to $100 and adjusted their earnings forecasts accordingly.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 00522
Unlock Now
Nomura
Buy
maintain
$90 -> $125
2025-10-08
Reason
Nomura
Price Target
$90 -> $125
2025-10-08
maintain
Buy
Reason
The analyst rating for ASMPT (00522.HK) was lifted to a Buy with an increased target price from HKD90 to HKD125 due to the company's qualification by a leading wafer manufacturer and its potential to become a second supplier of chip on wafer thermal compression bonding (TCB). Nomura's research report suggests that ASMPT has overcome previous obstacles and is likely to win next-generation oW TCB orders soon, indicating a positive outlook for future orders and potential revaluation.
Citi Research
Buy
maintain
$75 -> $85
2025-08-12
Reason
Citi Research
Price Target
$75 -> $85
2025-08-12
maintain
Buy
Reason
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
